JNJ241122C170000
- 0.01
- 0.000.00%
Johnson & Johnson Newsroom
Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program
Market Climbs, Bitcoin Close to $100k | Live Stock
Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis
Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and Others
Express News | Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya® (Guselkumab) in Ulcerative Colitis, a First for an Il-23 Inhibitor
Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days
Zevra Niemann-Pick Disease Type C Drug Miplyffa Now Available
Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are...
Bitcoin Hits $99k, Thursday Market Whiplash Following Nvidia Price | Wall Street Today
Express News | Health Canada Authorizes Carvykti® (Ciltacabtagene Autoleucel) for Patients With Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
Optimism Over Global Healthcare Sector Rises: Jefferies
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Bitcoin Hits $98k, Nvidia Falls on Forward Guidance, Google Chrome Break-Up | Live Stock
Price Over Earnings Overview: Johnson & Johnson
Nvidia Forward Guidance Was Not Perfect, Market Flat | Wall Street Today
J&J Loses Around $24B in a Month: How to Play the Stock?
Sector Update: Health Care Stocks Advance Wednesday Afternoon